Business Context and Reporting Period
This Form 8-K filing by Avalo Therapeutics, Inc. (AVTX) is dated October 3, 2023. The report announces the scheduling of the Company's 2023 Annual Meeting of Stockholders and establishes deadlines for shareholder proposals and director nominations.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and meeting logistics rather than financial performance.
Material Changes
The primary material change reported is the rescheduling of the 2023 Annual Meeting of Stockholders to December 5, 2023, at 9:30 a.m. EST. This date represents a change of more than 30 days from the anniversary of the 2022 Annual Meeting, triggering specific disclosure requirements for shareholder proposals.
Guidance, Outlook, and Management Commentary
Management has not provided financial guidance or operational outlook in this filing. The Company indicated that additional details regarding the meeting location and specific matters to be voted upon will be included in the proxy statement to be filed with the SEC prior to the Annual Meeting.
Important Facts for Investors to Verify
- Annual Meeting Date: December 5, 2023, at 9:30 a.m. EST.
- Record Date: October 12, 2023 (close of business) for determining stockholders entitled to vote.
- Rule 14a-8 Proposal Deadline: October 10, 2023, for proposals to be included in proxy materials.
- Bylaw Proposal/Nomination Deadline: October 13, 2023, for business brought before the meeting outside of Rule 14a-8 or for director nominations.
- Universal Proxy Notice Deadline: October 13, 2023, for shareholders soliciting proxies for director nominees other than the Company's nominees.
- Submission Address: 1500 Liberty Ridge Drive, Suite 321, Wayne, Pennsylvania 19087.